Moderator: Monica Andrade De Orbe, GINN | Asociacion de Bolsas de Nicotina (ABN)
Discussion Leaders:
- Dr Sydney Hiller, Director of US Regulatory Operations, Inter‑Scientific
- Tim Phillips, Founder, Tamarind Intelligence
As the US, EU and LATAM evolve along sharply different regulatory paths, companies need evidence packages that can withstand scrutiny across all three.
This session outlines a reusable, region agnostic evidence engine — covering RWE (Real World Evidence), APPH (Appropriate for the Protection of Public Health) ready structures and governance — designed to support predictable market access from Washington to Brussels to Buenos Aires.
Global Institute for Novel Nicotine (GINN) brings two high impact commercial sessions to InterTabac this year, focused squarely on the market access challenges shaping the next decade.
Panel 1 We’re Right but We’re Losing – How the Nicotine Sector Wastes Its Own Advantage confronts the sector’s biggest strategic blind spot: despite strong science, companies continue to invest heavily in brand level competition while under funding the evidence, enforcement and regulatory infrastructure that determines commercial survival.
Location: Main Stage | Entrance North, 16.09.2026 at 11 am
Deep Dive 2 Making Evidence Travel: A Three‑Region Blueprint for Market Access then provides the solution — a practical, three region evidence engine built to travel across FDA expectations, EU debates and LATAM’s emerging post prohibition frameworks. Together, these sessions offer manufacturers, distributors, and investors a clear roadmap for protecting access, reducing regulatory risk, and positioning for growth in the world’s most consequential markets.
Location: London | Conference Area, 16.09.2026 at 1 pm